Table 1.
Demographic and clinical characteristics of the COVID-19 patients included.
| Total (n = 114) | Death group (n = 46) | Discharged group (n = 68) | P-values | |
|---|---|---|---|---|
| Age (years) | 61.74 ± 13.57 | 65.93 ± 8.49 | 58.60 ± 15.47 | 0.002 |
| Sex | 0.015 | |||
| Female % | 53 (46.50) | 15 (32.61) | 38 (55.88) | |
| Male % | 61 (53.50) | 31 (67.39) | 30 (44.12) | |
| Smoker % | 45 (39.47) | 23 (50.00) | 22 (32.35) | 0.059 |
| Comorbidities % | 65 (57.02) | 30 (65.22) | 35 (51.47) | 0.146 |
| Diabetes mellitus | 27 (23.68) | 14 (30.43) | 13 (19.12) | 0.163 |
| Cardiovascular disease | 12 (10.53) | 3 (6.52) | 9 (13.24) | 0.252 |
| COPD | 5 (4.39) | 3(6.52) | 2(2.94) | 0.360 |
| Hypertension | 50(43.86) | 23(50.00) | 27(39.71) | 0.277 |
| Length of stay (days) | 19.56 ± 15.91 | 11.48 ± 8.79 | 25.28 ± 17.34 | <0.001 |
| White blood cell count (× 109/L) | 7.90 ± 5.80 | 14.21 ± 8.18 | 5.87 ± 2.70 | <0.001 |
| Lymphocyte count (× 109/L) | 1.15 ± 0.57 | 0.77 ± 0.35 | 1.25 ± 0.59 | <0.001 |
| Neutrophil count (× 109/L) | 6.22 ± 5.98 | 13.04 ± 8.51 | 4.09 ± 2.66 | 0.001 |
| Monocyte count (× 109/L) | 0.42 ± 0.20 | 0.44 ± 0.23 | 0.41 ± 0.19 | 0.766 |
| C-reactive protein (mg/L) | 44.58 ± 54.27 | 122.96 ± 62.13 | 28.44 ± 38.48 | <0.001 |
| Ferritin (ng/ml) | 792.78 ± 684.73 | 1315.06 ± 653.17 | 423.81 ± 423.79 | <0.001 |
| Alpha fetoprotein (ng/ml) | 2.48 ± 1.64 | 1.75 ± 0.85 | 2.98 ± 1.84 | <0.001 |
| Carcinoembryonic antigen (ng/ml) | 8.23 ± 10.64 | 14.80 ± 14.20 | 3.80 ± 2.43 | <0.001 |
| Interleukin 6 (pg/ml) | 22.30 ± 39.59 | 41.95 ± 40.11 | 20.10 ± 39.66 | 0.381 |
COPD, chronic obstructive pulmonary disease. Continuous variables are showed as mean ± SD.